Here, we will discuss the biology of KRAS in NSCLC, in particular KRAS G12C, with a specific focus on primary and secondary resistance mechanisms, their possible clinical implications and future research perspectives. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.